feel free to contact us and we will
get back to you as soon as we can.
  • Head Office
  • Gwanggyo R&D Center
  • USA Office

(34141) BVC #121, 125 Gwahak-ro, Yuseong-
gu, Daejeon, Repulic of Korea

Google map

  • TEL + 82-70-8723-0566
  • FAX + 82-70-7966-0567

(16229) 2F GyeongGi-do Business & Science Accelerator, 107 GwangGyo-ro, YeongTong-gu, SuWon-ci, GyeongGi-do, Republic of Korea

Google map

  • TEL + 82-31-213-0566
  • FAX + 82-31-213-0567

9550 Zionsville Rd Suite 1, Indianapolis, IN 46268, United States

Google map

Standard Radiopharmaceuticals
for Theragnostic Oncology


The TERACARRIER™ functions as an all-integrative Radiopharmaceutical Platform for any existing Radioligands & Isotopes. It is the first & only technology in the world that can fully bind-lock the radioisotopes, with the targeting ligands, within the iron-oxide nano-particle based core. Unlike conventional chelators/linkers, ZTI’s carrier physically locks the radioisotopes within, TERACARRIER™ based drugs are immune to chemical leeching of radioisotopes within the body. This tech will improve targeting rate of radiopharmaceuticals and prevent off-target side effects from free isotopes broken off the drugs. ZTI tech will standardize the development of radiopharmaceuticals, bringing exponential versatility in indications and pipelines, providing a symbiotic platform for every existing oncological Radioligand Therapy.